Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.4.1 (phosphodiesterase)
18,767 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The amounts of released soluble (s) antigen of influenza A/WSN virus were increased when the virus was allowed to interact with isolated plasma membranes in a medium containing substances enhancing the level of adenosine 3',5' cyclic monophosphate (c'AMP) or activating the enzyme adenylate cyclase. By contrast, less s-antigen was released upon addition to the incubation medium of foetal calf serum or calf serum proteins which activate c'AMP phosphodiesterase and thus decrease the level of c'AMP. Changes in the amount of released s-antigen were parallelled by changes in the activities of membrane Ca-adenosine triphosphatase and creatine phosphokinase.
...
PMID:Interaction of plasma membranes with influenza virus. VI. The possible role of the adenylate cyclase system. 0 18

In chick embryo cells (CEC) and plasma membranes (PM) isolated therefrom, three forms of 3',5'-cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) were demonstrated: (1) PDE activated only by Ca2+ (Ca-PDE); (2) PDE activated only by Mg2+ (Mg-PDE); and (3) PDE stimulated in the presence of 2 mM Mg2+ by low concentrations of Ca2+ (Ca-Mg-PDE). Purified influenza A virus, under suitable conditions, lowered the activities of these PDEs. The decrease was greater in samples incubated in the presence of adenosine triphosphate (ATP) than in those incubated in its absence.
...
PMID:Interaction of plasma membranes with influenza virus. VII. Effect on 3',5'-cyclic adenosine monophosphate phosphodiesterase activity. 1 92

Calcium-dependent regulator protein (CDR) and CDR-dependent 3',5'-c AMP-phosphodiesterase were isolated and partially purified from 12-day chick embryos. Some basic properties of the preparations obtained were described. Native (infectious) but not noninfectious (heat-inactivated) influenza virus in the presence of CDR and ATP reduced the activity of CDR-dependent phosphodiesterase.
...
PMID:Role of calcium dependent regulator protein (CDR) in inhibition of 3',5'-c AMP-phosphodiesterase by influenza virus. I. Isolation and purification of CDR and CDR-dependent 3',5'-c' AMP-phosphodiesterase from chick embryos. 4 Apr 16

As revealed by spectrophotometry, native but not heat-inactivated influenza virus in the presence of ATP reduced the activity of calcium-dependent regulator protein-stimulated 3',5'-c AMP-phosphodiesterase (CDR-PDE). ATP could be partially replaced by ADP but not by AMP. The degree of CDR-PDE inhibition increased with increasing virus concentration. But at very high virus concentrations the rate of 3',5'-c AMP hydrolysis by CDR-PDE was not linearly dependent on time. At appropriate virus concentrations the degree of inhibition of CDR-PDE activity remained unchanged for the whole reaction time.
...
PMID:Role of calcium-dependent regulator protein (CDR) in inhibition of 3',5'-c AMP-phosphodiesterase by influenza virus. II. Kinetic studies on inhibition of CDR-dependent phosphodiesterase by influenza virus. 4 Apr 17

Influence of chlorpromazine (CPZ) on the production of influenza virus was followed in chick embryo cell (CEC) monolayers. CPZ--which binds specifically to calmodulin (CaM)--inhibited in concentration of 20-100 mumol/l the activity of CaM-stimulated 3', 5'-c'AMP phosphodiesterase (PDE). When administered together with the virus, CPZ in concentrations of 20-50 mumol/l reduced virus yields by 2-3 log PFU. Addition of CPZ 15 min before or 1 hr after influenza virus adsorption had no effect. The inhibitory action of CPZ was reversed by purified CaM. The adsorption of influenza virus to CEC or to erythrocytes was not affected. The participation of CaM on the mechanism of influenza virus penetration is discussed.
...
PMID:Influence of chlorpromazine on the replication of influenza virus in chick embryo cells. 612 27

A ribonuclease activity associated with influenza virus has been purified to homogeneity. This preparation is free of DNAase, phosphodiesterase, and phosphatase activities. The purified enzyme has a pH optima of 7.0 at 37 degrees C, and moves as a single band on sodium dodecyl sulfate - polyacrylamide gel with an estimated molecular weight of 84 000.
...
PMID:The isolation and properties of a ribonuclease associated with influenza virus. 738 74

BRL 61063 is a novel xanthine phosphodiesterase (PDE) type IV inhibitor with selective inhibitory activity for tumor necrosis factor (TNF) alpha production. This compound inhibits TNF alpha production by activated human blood monocytes in vitro and in animal models of endotoxemia and influenza infection. Inhibition of TNF alpha may be beneficial in many diseases; however, little is known about potential adverse effects of such inhibition on host defense. In an ex vivo study, we examined the effect of BRL 61,063 on the microbicidal and tumoricidal activity of pulmonary lavage cells during a local inflammatory response in rats challenged with Poly I:C. Pentoxifylline, a PDE inhibitor which also blocks TNF alpha production, was used for comparison. Treatment with BRL 61063 or pentoxifylline did not block the inflammatory response to Poly I:C or the activation of bronchoalveolar lavage (BAL) cells but reduced the level of tumoricidal activity attained. At the dosages used, pentoxifylline was more inhibitory than BRL 61063. Drug treatment did not prevent further stimulation of tumoricidal activity by LPS in vitro. LPS-stimulated cells from BRL 61063-treated rats reached a level of activation similar to the control group while the LPS-stimulated activity of BAL cells from pentoxifylline treated rats remained lower than control. Although pentoxifylline was more inhibitory for tumoricidal activity than BRL 61063, the latter was a more potent inhibitor of TNF alpha release as measured in vivo in LPS-challenged rats. This finding indicates that TNF alpha is not the main mediator involved in the activation of pulmonary macrophage tumoricidal function. Treatment with either BRL 61063 or pentoxifylline had little or no effect on the Poly I:C-induced candidacidal activity of BAL cells indicating that these compounds are unlikely to compromise non-specific host defense against infection.
...
PMID:Effect of TNF alpha production inhibitors BRL 61063 and pentoxifylline on the response of rats to poly I:C. 782 85

Our objective is to describe the basic chemical and biological properties of the new calmodulin antagonist HMN-709 (2-[N-(2-aminoethyl)-N-(4-chlorobenzenesulfonyl)]amino-N-(4-flu orocinnamyl)-N-methylbenzylamine). This newly synthesized compound was found to inhibit the Ca2+/calmodulin-dependent activation of calmodulin kinase I, smooth muscle myosin light chain kinase and Ca2+-phosphodiesterase with IC50 values of 1.57+/-0.21, 2.29+/-0.09 and 0.30+/-0.08 microM (mean+/-S.E.), respectively. This compound showed little or no effect on the Ca2+/calmodulin-independent activation of protein kinase A, protein kinase C and basal phosphodiesterase. In addition, HMN-709 inhibited calmodulin kinase I competitively with respect to calmodulin (Ki=0.88 microM) and non-competitively with respect to ATP. Affinity chromatography, with HMN-709-coupled Sepharose HP, showed that the compound bound to calmodulin in a Ca(2+)-dependent manner and did not bind to calmodulin kinase I. These results suggest that HMN-709 antagonizes calmodulin by binding to Ca2+/calmodulin. HMN-709 inhibited collagen-induced platelet aggregation with an IC50 value of 11.80+/-0.86 microM (mean+/-S.E.) without inhibiting phorbol 12,13-dibutyrate-induced aggregation at doses up to 12 microM. HMN-709 appears to be a new, membrane-permeable calmodulin antagonist that may be used for studying the involvement of calmodulin in cellular processes.
...
PMID:HMN-709, a chlorobenzenesulfonamide derivative, is a new membrane-permeable calmodulin antagonist. 891 14

By 2020, chronic obstructive pulmonary disease (COPD) will become the third leading cause of mortality and fifth leading cause of disability worldwide. Although traditionally therapeutic nihilism has dominated the approach to the management of COPD patients, it is becoming increasingly clear that COPD is a highly preventable and treatable condition. Smoking cessation is the most important therapy because it is the only intervention that has been shown to modify the accelerated decline in lung function that is characteristic of COPD. Domiciliary oxygen therapy for those who are hypoxemic at rest results in improved survival. Vaccinations and immunizations against influenza and pneumococcus should be encouraged. Bronchodilators are used for symptomatic relief. Recent introduction of long-acting bronchodilators facilitates good control of dyspnea with once or twice daily dosing. In conjunction with inhaled corticosteroids, they appear to produce added clinical benefits. Pulmonary rehabilitation and lung transplantation are other therapeutic options for select groups of patients. Many promising compounds are in various stages of development as future therapies in COPD. Drugs such as phosphodiesterase 4 inhibitors, tyrosine kinase blockers and peroxisome proliferator-activated gamma receptor agonists show great promise as disease-modifying agents in COPD.
...
PMID:Therapeutic options for chronic obstructive pulmonary disease: present and future. 1574 84

Erectile dysfunction is a common multifactorial complication of diabetes mellitus. In recent years, phosphodiesterase type 5 (PDE-5) inhibitors have been introduced in the management of erectile dysfunction. A recent Cochrane systematic review assessed the effects ofPDE-5 inhibitors in patients with diabetes mellitus and erectile dysfunction from 8 randomized placebo-controlled trials (a total of 1759 participants). The duration of therapy was mainly 12 weeks. The weighted mean difference (WMD) for the International Index of Erectile Function (erectile dysfunction domain) at the end of the study period was 6.6 in favour of the PDE-5 inhibitors arm. The relative risk for answering 'yes' to a global efficacy question ('did the treatment improve your erections?') was 3.8 in the PDE-5 inhibitors arm compared with the control arm. Headache and flushing were the most common adverse events, followed by flu-like symptoms, dyspepsia, myalgia, vision disorders and lower back pain. The overall risk ratio for developing any adverse reaction was 4.8 in the PDE-5 inhibitors arm as compared to the control arm. It was concluded that sufficient evidence exists that treatment with PDE-5 inhibitors can improve erectile dysfunction in diabetic men.
...
PMID:[From the Cochrane Library: Phosphodiesterase inhibitors are effective in treating erectile dysfunction in diabetic men]. 1794 26


1 2 Next >>

---